1. Home
  2. BACQ vs SEPN Comparison

BACQ vs SEPN Comparison

Compare BACQ & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BACQ
  • SEPN
  • Stock Information
  • Founded
  • BACQ 2024
  • SEPN 2022
  • Country
  • BACQ United States
  • SEPN United States
  • Employees
  • BACQ N/A
  • SEPN N/A
  • Industry
  • BACQ
  • SEPN
  • Sector
  • BACQ
  • SEPN
  • Exchange
  • BACQ NYSE
  • SEPN NYSE
  • Market Cap
  • BACQ 333.2M
  • SEPN 311.6M
  • IPO Year
  • BACQ 2024
  • SEPN 2024
  • Fundamental
  • Price
  • BACQ $10.24
  • SEPN $9.25
  • Analyst Decision
  • BACQ
  • SEPN Buy
  • Analyst Count
  • BACQ 0
  • SEPN 4
  • Target Price
  • BACQ N/A
  • SEPN $27.00
  • AVG Volume (30 Days)
  • BACQ 53.6K
  • SEPN 2.6M
  • Earning Date
  • BACQ 01-01-0001
  • SEPN 05-15-2025
  • Dividend Yield
  • BACQ N/A
  • SEPN N/A
  • EPS Growth
  • BACQ N/A
  • SEPN N/A
  • EPS
  • BACQ N/A
  • SEPN N/A
  • Revenue
  • BACQ N/A
  • SEPN $977,000.00
  • Revenue This Year
  • BACQ N/A
  • SEPN N/A
  • Revenue Next Year
  • BACQ N/A
  • SEPN N/A
  • P/E Ratio
  • BACQ $113.74
  • SEPN N/A
  • Revenue Growth
  • BACQ N/A
  • SEPN 108.76
  • 52 Week Low
  • BACQ $9.80
  • SEPN $4.17
  • 52 Week High
  • BACQ $10.24
  • SEPN $28.99
  • Technical
  • Relative Strength Index (RSI)
  • BACQ N/A
  • SEPN N/A
  • Support Level
  • BACQ N/A
  • SEPN N/A
  • Resistance Level
  • BACQ N/A
  • SEPN N/A
  • Average True Range (ATR)
  • BACQ 0.00
  • SEPN 0.00
  • MACD
  • BACQ 0.00
  • SEPN 0.00
  • Stochastic Oscillator
  • BACQ 0.00
  • SEPN 0.00

About BACQ BLEICHROEDER ACQUISITION CORP. I

Bleichroeder Acquisition Corp I is a blank check company.

About SEPN SEPTERNA INC

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Share on Social Networks: